3 results
ThThe primary efficacy objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non-inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent VTE in patients with cancer who have completed at…
To assess uptake (visual and quantitative) of 89Zr-ipilimumab in tumor lesions and biodistribution at start of nivolumab/ipilimumab therapy Secondary1. To determine the correlation between tumor targeting of ipilimumab and response to therapy.2. To…
To investigate how safe the new medicine pralsetinib is when it is administered to patients with non-resectable advanced solid tumor cancers including non-small cell lung cancer (NSCLC) and Thyroid cancers.